MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera

Condition:   Polycythemia Vera Interventions:   Drug: Ruxolitinib;   Drug: Hydroxycarbamide;   Drug: Interferon-Alpha Sponsors:   University of Birmingham;   Novartis;   MPN Voice;   National Cancer Institute, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials